

# MANIF-2000 FOLLOWED BY MANIF-2 - Cohort of HIV-Seropositive Individuals Infected by Use of Intravenous drugs: Prospective Study in Marseille, Avignon, Nice and Ile-de-France

Head :Carrieri Maria-Patrizia, ORS PACA - INSERM U912  
Obadia Yolande, ORS PACA

Last update : 09/05/2017 | Version : 3 | ID : 60063

General	
Identification	
Detailed name	Cohort of HIV-Seropositive Individuals Infected by Use of Intravenous drugs: Prospective Study in Marseille, Avignon, Nice and Ile-de-France
Sign or acronym	MANIF-2000 FOLLOWED BY MANIF-2
CNIL registration number, number and date of CPP agreement, AFSSAPS (French Health Products Safety Agency) authorisation	Accord CNIL
General Aspects	
Medical area	Infectious diseases
Health determinants	Addictions
Keywords	related diseases, hepatic, psychiatric, genital and gynaecological, secondary side-effects from treatment, Health episodes, cardiovascular, neurological, infectious, prevention
Scientific investigator(s) (Contact)	
Name of the director	Carrieri
Surname	Maria-Patrizia
Address	13006 MARSEILLE
Phone	+ 33 (0)4 96 10 28 75
Email	Pmcarrieri@aol.com
Unit	ORS PACA - INSERM U912
Organization	OBSERVATOIRE REGIONAL DE LA SANTE

Name of the director	Obadia
Surname	Yolande
Address	13006 MARSEILLE
Phone	+33 (0)4 91 59 89 10
Email	yolande.obadia@inserm.fr
Unit	ORS PACA
Organization	OBSERVATOIRE REGIONAL DE LA SANTE
Collaborations	
Participation in projects, networks and consortia	Yes
Funding	
Funding status	Mixed
Details	ANRS, Conseil Général des bouches du Rhône, SIDACTION
Governance of the database	
Sponsor(s) or organisation(s) responsible	OBSERVATOIRE REGIONAL DE LA SANTE PACA
Organisation status	Public
Additional contact	
Main features	
Type of database	
Type of database	Study databases
Study databases (details)	Longitudinal study (except cohorts)
Database recruitment is carried out by an intermediary	A selection of health institutions and services
Database recruitment is carried out as part of an interventional study	No
Additional information regarding sample selection.	Prospective Inclusion cut-off date: 01/07/1998

## Database objective

### Main objective

General objective: MANIF 2000 is a cohort of HIV-1 seropositive patients that have been infected through intravenous drug use. Patients should have an initial CD4 count of  $> 300/\text{mm}^3$ . The initial aim of this study was to compare HIV progression according to whether patients were still active addicts, substituting or sober. This goal was revised in light of the changes in HIV history with the release of highly active combination therapy and the treatment of addicts with buprenorphine substitution. MANIF 2000 has become an observational cohort study focused on risk-related sexual behaviours associated with drug addiction, as well as adherence to therapy and interaction between substitution and treatment. Secondary objectives: - To determine the impact of depression and HIV treatment adherence on clinical progression; - to determine the impact of retention in substitution treatment on virological success.

### Inclusion criteria

HIV-1 or HIV-2 seropositive patients that have been infected through intravenous drug use with an initial CD4 count greater than  $300/\text{mm}^3$  and at clinical stage A or B.

## Population type

### Age

Adulthood (19 to 24 years)  
Adulthood (25 to 44 years)  
Adulthood (45 to 64 years)

### Population covered

Sick population

### Gender

Male  
Woman

### Geography area

Local

### Detail of the geography area

Multicentric cohort throughout France (10 centres):  
Marseille, Avignon, Nice, Ile de France

## Data collection

### Dates

Date of first collection (YYYY or MM/YYYY)

07/1995

Date of last collection (YYYY or MM/YYYY)

06/2006

## Size of the database

Size of the database (number of individuals) < 500 individuals

Details of the number of individuals 467

## Data

Database activity Data collection completed

Type of data collected  
Clinical data  
Declarative data  
Paraclinical data  
Biological data

Clinical data (detail)  
Direct physical measures  
Medical registration

Declarative data (detail)  
Paper self-questionnaire

Paraclinical data (detail)  
Puncture, biopsy

Biological data (detail)  
Type of samples taken: Haematology, chemistry, immunology, HIV serology, viral load, other serological tests such as Hepatitis B and C and freezing.

Presence of a biobank Yes

Contents of biobank  
Serum  
Plasma

Details of biobank content  
Serum bank, plasma bank

Health parameters studied  
Health event/morbidity  
Health event/mortality  
Health care consumption and services

Care consumption (detail)  
Hospitalization  
Medical/paramedical consultation  
Medicines consumption

## Procedures

Data collection method  
Self-administered questionnaire: entry from a paper questionnaire  
Interviews: entry from a paper questionnaire  
Clinical examinations: handwritten.

Participant monitoring Yes

Details on monitoring of participants	Follow-up duration: 11 years
Links to administrative sources	No
Promotion and access	
Promotion	
Link to the document	<a href="http://tinyurl.com/Hal-MANIF-2000">http://tinyurl.com/Hal-MANIF-2000</a>
Description	List of publications in HAL
Link to the document	<a href="http://tinyurl.com/Pubmed-MANIF-2000">http://tinyurl.com/Pubmed-MANIF-2000</a>
Description	List of publications in Pubmed
Access	
Terms of data access (charter for data provision, format of data, availability delay)	Data may not be used by academic teams Data may not be used by industrial teams
Access to aggregated data	Access on specific project only
Access to individual data	No access